Active, Not Recruiting
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
NCT03836352
- Conditions
- Adenocarcinoma, Adnexal Diseases, Bladder Cancer, +39 more
- Locations
-
- The University of Arizona Cancer Center Tucson, Arizona, United States
- Cedars Sinai Medical Center: Samuel Oschin Comprehensive Cancer Center Los Angeles, California, United States
- Boca Raton Regional Hospital, Lynn Cancer Institute Boca Raton, Florida, United States
- Hematology Oncology Associates of the Treasure Coast Port Saint Lucie, Florida, United States